$144.24
Closed
-(-)

At close

Financial advisor consultation illustration
Get professional financial guidance

Schedule your free first call with a financial advisor on CUSP Wealth
*T&Cs apply

About

Repligen Corp. is a global life sciences company, which engages in providing bioprocessing technologies and solutions used in the process of manufacturing biological drugs. The company is headquartered in Waltham, Massachusetts and currently employs 2,000 full-time employees. Its franchises include filtration, chromatography, process analytics and proteins. Its filtration franchise includes product offering covering upstream and downstream technologies. Its filtration products include XCell Alternating Tangential Flow (ATF) Cell Retention Systems, Flat Sheet Cassettes, Hollow Fiber Consumables, Tangential Flow Filtration Systems and Fluid Management. Its chromatography franchise includes products used in downstream purification, development, manufacturing and quality control of biological drugs. Its chromatography franchise includes OPUS Pre-Packed Columns, KRM Chromatography Systems and other additional chromatography products. Its process analytics include Downstream process analytical technology (PAT) and Upstream PAT. Its Proteins include Protein A Affinity Ligands, AVIPure Resins for New Modalities and Growth Factors.
Country

US

CEO

Mr. Olivier Loeillot

IPO date

1986

Employees

2,000

ISIN

US7599161095

Key stats

Open

$143.94

Volume

667.27K

Market cap

$8.12B

Prev. close

$143.94

Impl / hst vl

-

Open interest

$0.00

$141.83

Day’s Range

$145.18

$100.99

52W Range

$175.77

Valuation

44
Valuation score
Fairly Valued
P/E
156.52
P/S
10.54
P/B
3.82
Current ratio
9.20
Debt / Equity
-0.02
ROE
2.46%
Gross margin
55.74%
Income growth
-37.28%
FCF growth
34.22

Analysts estimates

Consensus rating
Buy

The average rating from top 16 analysts indicates that stock is expected to perform in line with the market

Str. Sell
Sell
Hold
Buy
Str. Buy
Avg. price target
$181.30
The top 22 analysts forecasts that 12-month price may increase by 25.70%, with a low of $143.42 and a high of $231.00
$143.42
Low
$181.30
Avg
$231.00
High
Current price

Earnings

Q1 ‘26 revenue
$194.26M
Q1 ‘26 net income
$8.33M
Revenue
Net income
Previous EPS
$0.48
Estimate EPS
$0.46
Actual EPS
Estimate EPS
Financial advisor consultation illustration
Get professional financial guidance

Schedule your free first call with a financial advisor on CUSP Wealth
*T&Cs apply